Second primary malignancy risk after Hodgkin lymphoma treatment among HIV-uninfected and HIV-infected survivors

Autor:	Renata Abrahão, Ann M. Brunson, Justine M. Kahn, Qian W. Li, Ted Wun, Theresa H. M. Keegan
Rok vydání:	2022
Předmět:	Risk Cancer Research Lymphoma Pediatric Cancer Clinical Sciences Immunology HIV Infections Article Rare Diseases Clinical Research Risk Factors Neoplasms Humans Survivors Cancer Pediatric Prevention Incidence Rehabilitation HIV Neoplasms Second Primary Hematology Hodgkin Disease population-based Second Primary Infectious Diseases Good Health and Well Being Oncology HIV/AIDS Infection second primary malignancy Hodgkin lymphoma
Zdroj:	Leuk Lymphoma Leukemia & lymphoma, vol 63, iss 5
ISSN:	1029-2403 1042-8194
Popis:	We compared secondary primary malignancy risk (SPM) in HIV-uninfected and HIV-infected Hodgkin lymphoma (HL) survivors. We used data from the California Cancer Registry on patients diagnosed with HL from 1990 to 2015 (all ages included), and standardized incidence ratios (SIRs) and multivariable competing risk models for analyses. Of 19,667 survivors, 735 were HIV-infected. Compared with the general population, the risk of SPM was increased by 2.66-fold in HIV-infected and 1.92-fold in HIV-uninfected survivors. Among HIV-infected survivors, median time to development of SPM was shorter (5.4 years) than in HIV-uninfected patients (8.1 years). Additionally, the highest risk of SPM was observed
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f62b8d55207800b25d3cb6a64e4b6fae https://doi.org/10.1080/10428194.2021.2020775 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.